REG - Futura Medical PLC - Directors’/PDMR Dealing and Grant of Options
10/10/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231010:nRSJ4757Pa&default-theme=true
RNS Number : 4757P Futura Medical PLC 10 October 2023
Futura Medical plc
("Futura" or the "Company")
Directors'/PDMR Dealing and Grant of Options
10 October 2023
Futura Medical plc (AIM: FUM) (the "Company"), the pharmaceutical company
developing innovative sexual health products, announces a grant of 10,590,675
options over Ordinary Shares ("Options") to employees and Directors.
Grant of Options
The Company has granted a total of 10,590,675 Options of which 4,084,681 have
been awarded to Directors as detailed below.
All Options have been granted under existing schemes, granting was subject to
the achievement of performance-based milestones and will vest equally over 3
years to October 2026 with 25% of the Options granted with immediate vesting.
The main ongoing vesting condition is that the individual remains an employee
or Director at the time of vesting.
Director Number of Options granted Exercise price Total number of Options held following grant
James Barder 1,450,211 0.2p 3,615,927
Angela Hildreth 1,267,742 0.2p 3,040,082
Ken James 1,366,728 0.2p 3,375,953
Full details of the Non-Executive Directors' remuneration will be included in
the Company's Annual Report & Accounts.
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.Futuramedical.com (http://www.Futuramedical.com)
Nomad and Sole Advisor
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Nick Bastin/ Jonathan Edwards/ Zoe Bolt/ Elena Bates
Email: futuramedical@optimumcomms.com (mailto:futuramedical@optimumcomms.com)
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys® technology. Each DermaSys® formulation is separately patented and
specifically tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and consumer
healthcare markets as appropriate. Development and commercialisation
strategies are designed to maximise product differentiation and value creation
whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a novel treatment for
erectile dysfunction (ED) through a unique evaporative mode of action. Futura
has conducted two Phase 3 studies using MED3000 in ED; FM57 study which
enabled Futura to be granted a CE Mark in 2021 and FM71 which enabled Futura
to be granted US marketing authorisation. Both studies demonstrated that
MED3000 presents an effective clinically proven treatment for ED with a rapid
speed of onset and a favourable benefit versus risk profile ideally suited for
an 'Over the Counter' classification.
Eroxon® is FDA approved in the US, CE marked in Europe and UKCA marked in
the UK as a clinically proven topical treatment for adult men with
erectile dysfunction under the brand Eroxon® with a key claim of "Helps you
get an erection within 10 minutes". Eroxon® is the agreed brand name in
certain regions such as the EU whereas MED3000 continues to be the internal
code name used by the Company and also in reference to countries where
regulatory approval or commercial distribution agreements have not yet been
achieved. www.eroxon.com (http://www.eroxon.com)
Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(http://www.futuramedical.com/) .
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name James Barder
2 Reason for the notification
a) Position/status Director/ PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Futura Medical plc
b) LEI 21380053QLT46UNV2303
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Options over Ordinary shares of 0.2p each
Identification code
GB0033278473
b) Nature of the transaction Grant of Options over Ordinary Shares
c) Price(s) and volume(s)
Price(s) Volume(s)
nil 1,450,211
d) Aggregated information
- Aggregated volume
Not applicable
- Price
e) Date of the transaction 9 October 2023
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregated volume
- Price
Not applicable
e)
Date of the transaction
9 October 2023
f)
Place of the transaction
Outside of trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Angela Hildreth
2 Reason for the notification
a) Position/status Director/ PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Futura Medical plc
b) LEI 21380053QLT46UNV2303
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Options over Ordinary shares of 0.2p each
Identification code
GB0033278473
b) Nature of the transaction Grant of Options over Ordinary Shares
c) Price(s) and volume(s)
Price(s) Volume(s)
nil 1,267,742
d) Aggregated information
- Aggregated volume
Not applicable
- Price
e) Date of the transaction 9 October 2023
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregated volume
- Price
Not applicable
e)
Date of the transaction
9 October 2023
f)
Place of the transaction
Outside of trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Ken James
2 Reason for the notification
a) Position/status Director/ PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Futura Medical plc
b) LEI 21380053QLT46UNV2303
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Options over Ordinary shares of 0.2p each
Identification code
GB0033278473
b) Nature of the transaction Grant of Options over Ordinary Shares
c) Price(s) and volume(s)
Price(s) Volume(s)
nil 1,366,728
d) Aggregated information
- Aggregated volume
Not applicable
- Price
e) Date of the transaction 9 October 2023
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregated volume
- Price
Not applicable
e)
Date of the transaction
9 October 2023
f)
Place of the transaction
Outside of trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHFSFFMUEDSEISRecent news on Futura Medical
See all newsREG - Futura Medical PLC - Results for the Year ended 31 December 2023
AnnouncementREG - Futura Medical PLC - Notice of Results and Investor Presentation
AnnouncementRCS - Futura Medical PLC - Eroxon to be available on prescription
AnnouncementREG - Futura Medical PLC - Trading Update
AnnouncementREG - Futura Medical PLC - Appointment of Joint Corporate Broker
Announcement